Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), University Hospital Erlangen, Erlangen, Germany.
Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), University Hospital Erlangen, Erlangen, Germany.
Matrix Biol. 2018 Aug;68-69:8-27. doi: 10.1016/j.matbio.2017.12.016. Epub 2018 Jan 31.
Transforming growth factor-β (TGF-β) is widely recognized as a core pathway of fibrosis. Inhibition of TGF-β signaling may thus offer potential for antifibrotic therapies. Long-term inhibition of TGF-β signaling at the level of its isoforms and receptors can be associated with unacceptable adverse effects. However, TGF-β regulates a myriad of intracellular signaling cascades to transmit its profibrotic effects and several of those pathways offer potential for pharmacologic intervention. Moreover, the multiple interactions of TGF-β with other profibrotic pathways also yielded candidates for therapeutic intervention. In this review, we discuss selected targets within the TGF-β pathway with high translational potential.
转化生长因子-β（TGF-β）被广泛认为是纤维化的核心途径。因此，抑制 TGF-β 信号可能为抗纤维化治疗提供潜力。在其同工型和受体水平上长期抑制 TGF-β 信号可能与不可接受的不良反应相关。然而，TGF-β 调节着无数的细胞内信号级联反应来传递其促纤维化作用，其中一些途径为药物干预提供了潜力。此外，TGF-β 与其他促纤维化途径的多种相互作用也为治疗干预提供了候选药物。在这篇综述中，我们讨论了 TGF-β 途径中具有高转化潜力的选定靶标。
